Revolutionizing the Treatment of Heart Failure with First-in-class Structural Heart Devices

Corvia Medical, Inc., previously DC Devices, Inc., is dedicated to revolutionizing the treatment of heart failure with first-in-class structural heart devices. The company has developed the world’s first transcatheter device designed to treat diastolic heart failure (DHF), also known as heart failure with preserved ejection fraction (HFpEF). The InterAtrial Shunt Device (IASD), also known as the Corvia™ Atrial Decompression System, is the world’s first transcatheter device approved in the European Union to treat HFpEF. By facilitating continuous and dynamic decompression of the left atrium, the IASD aims to improve heart failure symptoms and quality of life, decrease heart failure hospitalization rates, and reduce the overall cost burden of managing heart failure patients.

Year Invested: 2009
Location: Tewksbury, Mass.

Recent News

March 11, 2019
Corvia Medical Enters Into Agreement With Edwards Lifesciences, The Global Leader In Structural Heart Innovation

August 27, 2018
Corvia Medical Announces Strong Positive One-Year Data From Reduce LAP-HF I Randomized, Sham-Controlled Clinical Trial

November 14, 2017
Corvia Medical Announces Enrollment of First Patients in Pivotal Trial of the IASDĀ® System II for the Treatment of Heart Failure

Read More News

Associated Team Members

Mark Levin